Abstract:
본 발명은 스파이로키랄 탄소 골격을 갖는 신규한 화합물, 그의 입체이성질체, 그의 거울상이성질체, 생체 내에서 가수분해 가능한 그의 전구체 또는 약제학적으로 허용 가능한 그의 염을 제공한다. 상기 스파이로키랄 탄소 골격을 갖는 신규한 화합물은 조골세포 분화능이 우수하며, 비만세포 분화억제능 및 간에서의 지방산 합성 억제능을 가지므로, 골다공증, 지방간 및 비만치료에 획기적인 역할을 할 것으로 기대된다.
Abstract:
Provided are a novel compound with a spiro chiral carbon backbone, a stereoisomer thereof, an enantiomer thereof, an in vivo hydrolysable precursor thereof, or a pharmaceutically acceptable salt thereof. The novel compound with the spiro chiral carbon backbone has excellent osteoblast differentiation activity, mast cell inhibitoryactivity, and fatty acid synthesis inhibitory activity in the liver. Therefore, the novel compound can be expected to play an innovative role in treatment of osteoporosis, fatty liver, and obesity.
Abstract:
PURPOSE: A novel compound having spiro chiral carbon skeleton is provided to suppress mastocyte differentiation and fatty acid synthesis and use in treating osteoporosis, fatty liver, and obesity. CONSTITUTION: A novel compound having spiro chiral carbon skeleton is denoted by chemical formula 1. A method for preparing the compound of chemical formula 1 comprises: a step of cutting and drying Phorbas sp. and extracting with C1-C4; a step of dividing the extracting with water and methylene chloride to remove solvent of organic layer; a step of distributing with mixture solution of normal hexane, methanol, and water; a step of removing solvent of methanol layer; and a step of performing chromatography to obtain fraction.